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Available online 9 November 2016The core symptoms of autism spectrum disorder are poorly treated with current medications. Symptoms of au-
tism spectrum disorder are frequently comorbid with a diagnosis of epilepsy and vice versa. Medically-super-
vised ketogenic diets are remarkably effective nonpharmacological treatments for epilepsy, even in drug-
refractory cases. There is accumulating evidence that supports the efﬁcacy of ketogenic diets in treating the
core symptoms of autism spectrum disorders in animal models as well as limited reports of beneﬁts in patients.
This study tests the behavioral effects of ketogenic diet feeding in the ELmouse, a model with behavioral charac-
teristics of autism spectrum disorder and comorbid epilepsy. Male and female EL mice were fed control diet or
one of two ketogenic diet formulas ad libitum starting at 5 weeks of age. Beginning at 8 weeks of age, diet proto-
cols continued and performance of each group on tests of sociability and repetitive behavior was assessed. A ke-
togenic diet improved behavioral characteristics of autism spectrum disorder in a sex- and test-speciﬁc manner;
ketogenic diet never worsened relevant behaviors. Ketogenic diet feeding improved multiple measures of socia-
bility and reduced repetitive behavior in femalemice, with limited effects inmales. Additional experiments in fe-
male mice showed that a less strict, more clinically-relevant diet formula was equally effective in improving
sociability and reducing repetitive behavior. Taken together these results add to the growing number of studies
suggesting that ketogenic and relateddietsmay provide signiﬁcant relief from the core symptoms of autism spec-
trum disorder, and suggest that in some cases there may be increased efﬁcacy in females.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Autism spectrum disorder (ASD) is frequently comorbid with epi-
lepsy, with 7%–21% of children diagnosed with ASD also having a diag-
nosis of epilepsy [1–5]. This range is likely due to sampling from
different populations, and is likely conservative. Among subgroups of
patients, a high seizure frequency or severity correlates with severityfe Science Center, Hartford, CT
in),
gmail.com (S.N. Bisnauth),
. This is an open access article underof core ASD symptoms (low sociability and communication; high repet-
itive/stereotyped behavior) and intellectual disability [1,4].
A substantial subset of patients with epilepsy have seizures that are
refractory to medications, and this subset is similarly high (up to one-
third) of those diagnosedwith both ASD and epilepsy [6]; pharmacolog-
ical attempts to ameliorate the core ASD symptoms of decreased socia-
bility and communication and increased repetitive and stereotyped
behaviors have had limited success. Some studies have noted improve-
ments, possibly relating to alleviating the diverse comorbidities found
in patients diagnosed with ASD (for instance, see [7]). However there
is poormeta-analytical evidence of any drug treatment signiﬁcantly im-
proving sociability [8]. Serotonin reuptake inhibitors were used to treat
repetitive behaviors in the past but are now considered to have little ef-
fect [9–11]; atypical antipsychotics might be useful in limiting this corethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Dietary constituents.
LabDiet 5001
(0.08:1)
Bio-Serv F3666
(3.0:1)
Bio-Serv F5140
(6.6:1)
Fats 5.7 76.7 69.0
Proteins 23.9 8.5 18.1
Vitamin mix
carbohydrates
NS 2.04 1.95
Mineral mix
carbohydrates
NS 0.41 0.77
Other carbohydrates 48.7 0.076 2.5
Fuel value 3.36 kcal/g 7.24 kcal/g 6.82 kcal/g
Values are % by weight of total, except for fuel values. AIN vitamin mix is 97.7% carbohy-
drate by weight. AIN mineral mixes are 22.1% (F5140) or 11.8% (F3666) carbohydrate by
weight. Protein percentages are calculated from casein, which is typically 89% protein,
plusmethionine. Added values of percentages donot reach 100% as there are unlisted con-
stituents. Ketogenic ratios are given in parentheses. Information obtained from company
product data. Abbreviation: NS, not speciﬁed.
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highlights the dearth of effective ASD treatments.
A ketogenic diet (KD) is very low in carbohydrate, and high in fat,
with a moderate and sufﬁcient level of protein. Multiple versions of
this metabolic therapy have been well established as remarkably effec-
tive nonpharmacological treatments for epilepsy, even in controlling
drug-refractory seizures [14–16] with many decades of clinical use
[17,18]. Strikingly, some refractory patients (consistently at least 10%–
15% across studies) become seizure-free, and at least 50% achieve over
50% seizure reduction [16,19–22]; a subset of patients can be weaned
off the KD and remain seizure-free [23,24]. These outcomes suggest a
long-lasting antiepileptogenic effect, possibly through epigeneticmech-
anisms [25]. The potential of KDs for antiepileptogenesis is supported by
diverse animal research [26–32].
Evidence is accumulating for clinically beneﬁcial effect of KDs in ASD
in pilot studies [33,34], case studies [35–37], and parental reports [38],
as well as in animal models [39–42]. Also, in girls with Rett syndrome
(a genetic syndrome in girls which includes seizures and some behav-
ioral features similar to ASD) KDs are clinically helpful with behavior
[43–45]. Improved behavior was also seen in animalmodels of Rett syn-
drome [46,47]. Reminiscent of the diverse etiology of ASD, there are
myriad animal models of ASD, ranging from constitutive or induced,
many with known genetic and/or environmental underpinnings.
Previous studies showing beneﬁcial effects of a KD in rodentmodels
of ASD have tested those without a comorbid seizure phenotype: it was
important to ascertain if the KD's effect was on the core behaviors of
ASD, or if effectswere secondary to reducing the comorbidity of seizures
[39]. These studies showed clear improvement in core symptoms, but to
date, however, thismetabolic therapy has not been tested in a clinically-
relevant model of comorbid autism and epilepsy. Furthermore previous
studies tested one KD variant - a formula with a N6:1 ratio of fat: (car-
bohydrate + protein). This formula is typically used in research, but is
a much higher ratio than prescribed clinically (typically between 1:1
and 4:1). Additionally, all previous studies were in male animals, and
ketogenic diet effects on females are underexplored [46,48].
Herewe tested the effects of KDs on behavior andblood chemistry in
both sexes of EL mice, an idiopathic model of comorbid epilepsy [49]
and ASD [50]. EL mice mimic human autism in that the etiology is un-
known and the pathology develops gradually after birth, and comple-
ment other mouse ASD models by also developing seizures, a common
comorbidity in patients. Previous studies have shown that KD feeding
is anticonvulsant and antiepileptic in these mice [27,51]. Therefore,
ourmajor goalwas to investigate if KD treatmentwould also ameliorate
the core ASD symptoms present in these mice. The effects of two KDs
with differing stringency were investigated in several standard assays
of ASD-like rodent behavior in EL mice of both sexes.
2. Methods
2.1. Animals
At weaning, EL mice littermates (initial breeders kindly provided by
T.N. Seyfried, Boston College, Chestnut Hill, MA) were housed in same-
sex cages (3–6/cage). Tests performed here are unaffected by KD feed-
ing in a mouse control strain [39]; here we focused on KD effects and
sex differenceswithin the EL strain. Atﬁveweeks of age, cages remained
on control diet (CD; LabDiet 5001, W.F. Fisher & Son, Somerville, NJ) or
were switched to one of two KDs (F3666 or F5140; BioServ,
Frenchtown, NJ). Initial weights of all groups were not signiﬁcantly dif-
ferent (within sexes). All diets were given ad libitum and fresh KD was
provided daily. Diet compositions and ketogenic ratios (i.e. the ratio of
fat to (protein+ carbohydrate) by weight) are listed in Table 1; hereaf-
ter, KDs will be referred to by these ratios. Because initial pilot studies
indicated that themore stringent 6.6:1 KD improved behavior primarily
in females, additional testing of the milder 3.0:1 KD focused on female
mice. All testing occurred at 8–9 weeks of age, i.e. between 3 and4 weeks of dietary treatment. This length of diet treatment was chosen
based on our prior observations that rodents are in signiﬁcant ketosis at
these times on these particular KDs and that KDshave signiﬁcant behav-
ioral and electrophysiological effects at these times including improve-
ments in autistic-type behaviors in the BTBR model [39,52–57].
Spontaneous overt convulsions begin in EL mice of both sexes at ages
that depend somewhat on the type and amount of handling, consistent
with the expected developmental progression of the phenotype, but
typically older than our testing age [58,59]. Behavioral seizures were
not an interfering factor in these studies: in viewing behavioral videos,
or during handling in behavioral or physiological experiments, we
never observed convulsions in our tested animals in any treatment
group. However seizures were noted in older adult male breeders -
thus conﬁrming the spontaneous seizure phenotype characteristic of
the EL strain.
2.2. Behavioral analysis
Testing occurred as described previously [39]. After 30min habitua-
tion to the testing roommicewere tested in the three chamber sociabil-
ity test [60]. Sociability testing occurred in three 10 min phases each
with free movement among the three chambers of a Plexiglas 3-cham-
ber apparatus. After an initial 10min habituation conﬁned to the center
chamber, phase 1 consisted of vacant inverted wire pencil cups (height,
10 cm; width at open end, 10 cm) in each side chamber (a test for side
bias). In phase 2, a “stranger” mouse (CD-1, an albino control strain) of
the same sex as the testmousewas corralled in thewire cage of one side
chamber (a test of sociability). During phase three, the ﬁrst (now famil-
iar) CD-1mouse remained in place and a newCD-1mousewas corralled
in the other wire cage (a test for preference for social novelty). Stranger
mouse placement was counterbalanced and stranger mice were fed on
the respective experimental diet for several days before testing to elim-
inate a possible confound of diet-related olfactory cues. Time spent in
each chamber was quantiﬁed for all phases; direct social contact
(nose/face/forepaw contact with the cups and/or stranger mice) was
quantiﬁed only for phases 2 and 3 and only for pencil cups corralling
stranger mice.
A standard test of self-grooming, a self-directed repetitive behavior,
was performed on a subsequent day: after 30 min habituation to the
testing room, mice were placed in a small empty cage (single cage,
non-social condition) with no bedding for 20 min; the last 10 min
were scored. Groomingwas also quantiﬁed from video in phases 1 (sol-
itary, non-social situation) and 2 (social situation) in the three-chamber
sociability test.
After blood testing of all groups (see below, physiological analysis),
passive social communication was assessed by social transmission of a
food preference (STFP) as described previously [39]. EL mice were ha-
bituated to eating KD or powdered CD, as appropriate, from glass jars
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3 day version, described below) were used; only one was administered
to a given mouse. Food ﬂavors: For both protocols, ﬂavors were cocoa
(2%) and cinnamon (1%) with each being the trained ﬂavor in half the
trials, and ﬂavor placement in the cages was counterbalanced. Jars
were weighed before and after presentation. 2-day protocol: An isolated
demonstrator mouse was fasted for 18 h, and presented with one jar of
powdered ﬂavored CD (“trained” ﬂavor) until it had eaten at least 0.5 g.
The demonstrator was returned to the home cage for 30min to interact
with cage-mate observermice (training), which had also been fasted for
18 h. Observer mice then moved to novel cages (one mouse per cage)
and were presented with both the “trained” ﬂavor (eaten by the dem-
onstrator) and an “untrained” ﬂavor (novel ﬂavored food) for 2 h. 3-
day protocol: An isolated demonstrator mouse was fasted for 18 h, and
presented with one jar of powdered ﬂavored food (“trained” ﬂavor)
until it had eaten at least 0.5 g. The demonstrator was returned to the
home cage for 30 min to interact with cage-mate observer mice (train-
ing). Observer mice were fasted for 18 h subsequent to exposure to the
demonstrator, and then presented with both the “trained” ﬂavor (eaten
by the demonstrator) and an “untrained” ﬂavor (novel ﬂavored food)
for 2 h. The 2- and 3-day methods differ in that A) the 3-day method
has an additional memory component in that the learning and testing
are separated by 18 h, and B) motivation to learn might be lower in
the 3-day protocol because observer mice are not in a fasted state dur-
ing training. In training and testing, all ﬂavored diets were powdered
CD. Use of the CD during training and testing is warranted even in KD-
fed mice because during training, when associative learning of the
food preference occurs (or not), the observer mice have yet to eat any
of the powdered CD; it alsomaintains a consistent diet during the train-
ing and the test.
2.3. Physiological analysis
Animals were weighed the day before behavioral testing com-
menced. Between the small cage grooming test and STFP, mice were
lightly anesthetized with isoﬂurane for tail blood collection; whole
blood was analyzed immediately for glucose and β-hydroxybutyrate
with Precision Xtra meters (Abbott Laboratories, Bedford, MA). Blood
was collected prior to STFP to avoid any confoundingmetabolic changes
due to eating ﬂavored CD in the STFP test phase.
2.4. Data analysis
Social and grooming behavior were scored ofﬂine from video by two
independent validated scorers, at least one of whomwas blind to treat-
ment. Data from each group for each measure were analyzed with
Grubb's test for outliers, which were eliminated from that test; there
were no outliers for body weight, blood glucose or blood β-
hydroxybutyrate. Data were analyzed using t-tests or ANOVA with
Bonferroni post-hoc tests using repeated measures where applicable.
Data are reported as mean ± standard error. The signiﬁcance level
was deﬁned as p b 0.05.
3. Results
3.1. Social behavior
One measure of social behavior in the 3-chamber test is time in the
side chambers. ELmice showed no side preference (phase 1) and no so-
cial preference: CD-fed EL mice were not signiﬁcantly social when a
mouse was present (phase 2), regardless of sex (Fig. 1; female CD:
side F1,34 = 2.6, n.s., phase F2,34 = 3.0, n.s., interaction F2,34 = 0.8 n.s.;
male CD: side F1,22 = 3.9, n.s., phase F2,22 = 0.2, n.s., interaction
F2,22 = 2.3, n.s.). However, feeding with either KD formula highly in-
creased sociability in females, i.e. increased time spent in the chamber
with another mouse (Fig. 1, top; 6.6:1 KD side F1,34 = 13.6, p b 0.01,phase F2,34 = 0.5, n.s., interaction F2,34 = 9.5, p b 0.001; 3:1 KD side
F1,32 = 12.2, p b 0.01, phase F2,32 = 7.2, p b 0.01, interaction F2,32 =
9.6, p b 0.001). There was signiﬁcantly improved sociability in phase 2
with KD feeding in males (Fig. 1, bottom; side F1,24 = 13.8, p b 0.01,
phase F2,24 = 8.9, p= 0.001, interaction F2,24 = 0.9, n.s.). In the test of
preference for social novelty (introduction of a new mouse, phase 3),
only 6.6:1 KD-fed females exhibited signiﬁcant preference (Fig. 1,
top), although the effect size appears small.
Another measure of social behavior in the 3-chamber test is social
contact. Treatment with either KD signiﬁcantly increased social contact
in females, regardless of whether therewas onemouse or two (phases 2
and 3, respectively; Phase F1,50 = 3.2, p = 0.08; Diet F2,50 = 13.4,
p b 0.001; Interaction F2,50 = 1.5, n.s.) There was no signiﬁcant effect
of KD feeding on social contact in males (Fig. 2; Phase F1,22 = 4.8,
p= 0.04; Diet F1,22 = 0.2, n.s.; Interaction F1,22 = 2.9, n.s.), which was
generally low and in the same range as the CD-fed females. This pattern
indicates that KD-fed males were preferring to spend time in the cham-
ber with the stranger mouse but were not highly investigative of or
interacting directly with the mouse - thus indicating only a limited
boost to sociability by KD feeding.
STFP test results were sex- and protocol-dependent. CD-fed female
EL mice preferred the trained ﬂavor and thus performed STFP success-
fully in protocols with or without a long-term memory component
(3 day vs. 2 day protocol, respectively; Fig. 3), and this result was main-
tained and not changed signiﬁcantly when female mice were fed KD in
either protocol (data not shown). Male EL mice fed CD successfully per-
formed STFP in the 2-day protocol but not the 3-day protocol, suggest-
ing a failure either to learn the ﬂavor or to remember the food
preference after an 18 h delay. Similar to the lack of a KD inﬂuencing
STFP in females, successful performance in the 2-day protocol was not
altered and the performance deﬁcit in the 3-day protocol was not alle-
viated by KD feeding in males (Fig. 3).
3.2. Repetitive behavior
Effects of KDs on repetitive behavior (self-grooming) were mixed
based on sex and environment. In the small cage (solitary, non-social)
test, grooming was decreased signiﬁcantly in males (t = 2.1,
*p b 0.05), but was not changed by KD feeding in females (Fig. 4;
F2,51 = 1.5, n.s.). In the 3-chamber test, grooming was high in phase 1
(non-social) in CD-fed females, and was lowered signiﬁcantly by either
KD; self-grooming in phase 2 (social) was not affected by the strict KD
but was signiﬁcantly elevated by the moderate KD (Fig. 5 top; Phase
F1,49 = 38.9, p b 0.001; Diet F2,49 = 1.7, n.s.; Interaction F2,49 = 13.0,
p b 0.001). For males in the 3-chamber test, grooming was low in
phase 1 and was not affected by KD feeding; phase 2 self-grooming
was also not affected (Fig. 5 bottom; Phase F1,23 = 20.8, p b 0.001;
Diet F1,23 = 1.9, n.s.; Interaction F1,23 = 1.9, n.s.).
3.3. Blood chemistry and body mass
Consistent with previous ﬁndings, feeding on either KD raised levels
of circulating ketones in all groups, butwith some sex-speciﬁc effects: in
females the stronger 6.6:1 KD caused stronger ketosis than the milder
KD (Table 2). Blood glucose results were more variable based on diet
and sex: blood glucose was mildly but signiﬁcantly reduced in females
by the 6.6:1 KD but not by the 3:1 KD; curiously, the stricter KD had
no signiﬁcant effect on glucose in males (Table 2). We replicated this
unexpected latter result in a separate group of males (n = 5, data not
shown). In addition, another group of males was left on the KD for a 6
wk. extended period of time: again, blood glucose was not signiﬁcantly
reduced (n=6, data not shown). The 6.6:1 KDdid not signiﬁcantly alter
weight in either sex, but females on the3:1 KDhad bodyweights elevat-
ed compared to females fed on either the CD or 6.6:1 KD (Table 2). All
diets were fed ad libitum, and these ﬁndings indicate that animals
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signiﬁcantly social (p=0.11), but those fed either KDwere highly social (middle). In the test for preference for social novelty, only those females fed the stricter KD signiﬁcantly preferred
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for the beneﬁcial behavioral effects observed here.
4. Discussion
Effects of two ketogenic diet formulas on core behavioral symp-
toms of ASD were assessed in both sexes of EL mice, a model ofidiopathic comorbid epilepsy and autism. The EL mouse behavioral
phenotype develops over time, consistent with many clinical cases
of autism. In addition, the ketogenic diet formulas applied here in-
cluded a ratio of fat to carbohydrate and protein within the range
of that administered routinely to children. Overall effects of two KD
formulas were positive or neutral on behavioral characteristics asso-
ciated with ASD.
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sexes fed a CD were asocial in the 3-chamber test of sociability. These
ﬁndings are consistent with previous work characterizing EL mice as
having low or abnormal sociability in various other paradigms [50,61–
63]. Notably, after KD feeding, females became highly social in the 3-
chamber test; there was moderately increased sociability in males.
However, a sex-speciﬁc deﬁcit in males in a socially-cued learning and
memory test (3-day STFP protocol) was not improved by a KD. Beyond
improved sociability, the relative amount of time spent on repetitive
self-directed behavior (grooming) in non-social situations was reduced
by ketogenic diet feeding in a test- and sex-speciﬁc manner and behav-
ioral improvements were very similar with 6.6:1 and 3:1 KDs. Phase 1
grooming in the CD-fed females was higher than in any other ASD
model that we have studied ([39]; unpublished data), andwas striking-
ly reduced by KD feeding. In general, these data are in accord with prior
studies ﬁnding beneﬁcial effects of KD feeding in other rodentmodels of
ASD (BTBR mouse, Engrailed 2 knockout mouse; prenatal valproic acid
treatment in rats) [39–42] and with limited clinical reports with similar
diets in ASD patients [33–38].
STFP results were sex-dependent as well. Female EL mice fed the
control diet performed the STFP test successfully in either a 2-day or
3-day protocol; results in males were mixed: control diet-fed male ELmice were apparently sufﬁciently social during training in the 2-day
protocol to learn the association of the demonstrator mouse and the
trained ﬂavor and thus prefer the trained ﬂavor in the immediate food
preference test (also showing that EL mice do not have impaired
olfaction). Males did not show this preference in the 3 day protocol
which incurs an additional memory component. Therefore, the poor
performance of male EL mice in the 3-day protocol is not due to low so-
ciability during training, suggesting amore speciﬁc memory deﬁcit, and
perhaps a social memory deﬁcit. However the 2- and 3-day protocols
differ in an important respect besides the delay between training and
testing: in the 2-day, but not the 3-day, protocol, test mice have been
fasted prior to (andmay bemoremotivated during) training. To address
this confound, we performed amodiﬁed 3-day protocol with fasting be-
fore training and testmice also showednopreference for the trainedﬂa-
vor. Therefore, differences in motivation during learning appear not to
be involved, and we conclude that the poor performance of male EL
mice in the 3-day protocol is due to a memory deﬁcit. A much shorter
delay might have been sufﬁcient to impair memory, as EL mice have a
social recognition memory deﬁcit over 30 min [62]. Nevertheless, KD
feeding did not improve male EL mouse memory in STFP. Similarly,
KD feeding did not improve EL mouse acquisition of an associative pro-
cedural task in the radial water maze [27].
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143D.N. Ruskin et al. / Physiology & Behavior 168 (2017) 138–145In addition to behavioral problems, maturing EL mice develop epi-
lepsy that can be treated and prevented by KD feeding [27]. This im-
provement is thought to depend on reduced blood glucose: decreased
blood glucose correlatedwith decreased seizures [31,64]. Indeed, caloric
restriction alone has seizure-reducing effects in EL mice [64,65]. In par-
allel, evidence is building that limiting glucose is anticonvulsant
through an adenosine-based mechanism [54,56,66] and we hypothe-
sized that ASD core symptoms could be alleviated by this same mecha-
nism [67]. Here, for ASD-like symptoms, there appears to be a
dissociation among caloric restriction, KD, and blood glucose. First, be-
havioral improvement occurred in females with the 6.6:1 KD without
signiﬁcant weight loss and, strikingly, also with the 3:1 KD which in-
curred signiﬁcant weight gain. Secondly, although blood glucose was
signiﬁcantly lowered in females fed the 6.6:1 KD, this drop did not
occur in those fed the 3:1 KD yet the behavioral effects of both KDs
were similar. Also, themild behavioral improvements inmales occurred
without changes in weight or blood glucose. We conclude that a caloric
restriction component to KDs [68] is not necessary for behavioral bene-
ﬁts in this model and appears not to be necessary in at least some of the
clinical ASD reports [33,34,37]. Glucose is not likely to be irrelevant,
however: blood levels of glucose are notably stable on minutes-to-
hours timescales during KD feeding [69,70], and recently a low glycemic
index dietwas shown to improve ASD-like behaviors in the BTBRmousemodel [71]. In this latter paper, however, dietary treatment was started
in the mothers of the test mice before conception, and so beneﬁcial ef-
fects could be developmental rather than therapeutic.
In addition to reduced glucose, the eponymous blood chemistry hall-
mark of KDs is ketosis. Male EL mice fed the 6.6:1 KD had elevated β-
hydroxybutyrate (similar to females fed themilder 3:1 KD) and showed
improved sociability but not strong and signiﬁcant improvements like
females. Thus ketosis is not proven to be sufﬁcient for improved socia-
bility, though it may be necessary. A high fat content is likely also not
sufﬁcient: a high-fat non-ketotic diet worsens behavior and cognition
in the BTBR ASD model [72]. However, a recent case report described
a striking improvement in ASD behaviors (as well as seizures) with a
diet rich in medium-chain triglycerides [37]. This type of fat is rapidly
absorbed and metabolized to ketone bodies in the absence of dietary
carbohydrate restriction (although downstream effects of this fat are
difﬁcult to disentangle from glucose metabolism [66,73]). Also,
concerning seizures, evidence is mounting for medium-chain fatty acid
actions apart from ketone body elevation [74,75]. More studies of medi-
um-chain triglycerides and fatty acids and ketone body-augmenting
Table 2
Physiological parameters.
Sex and diet Female CD
n = 18
Female 6.6:1 KD
n = 18
Female 3:1 KD
n = 18
Male CD
n = 12
Male 6.6:1 KD
n = 14
Body weight (g) 22.4 ± 0.4 20.7 ± 0.4 28.2 ± 0.7⁎⁎⁎,§§§ 25.6 ± 0.4 25.4 ± 0.8
Blood glucose (mg/dL) 154 ± 4 135 ± 6⁎ 145 ± 4 147 ± 8 153 ± 5
Blood β-HB (mM) 0.30 ± 0.02 1.62 ± 0.13⁎⁎⁎ 0.91 ± 0.08⁎⁎⁎,§§§ 0.28 ± 0.03 1.04 ± 0.09⁎⁎⁎
Females: weight ANOVA F2,51= 54.8, p b 0.001; glucose ANOVA F2,51= 4.0, p b 0.05;β-hydroxybutyrate ANOVA F2,51= 60.3, p b 0.001. Bonferroni post hocs - ⁎p b 0.05, ⁎⁎⁎p b 0.001 com-
pared to CD; §§§p b 0.001 compared to 6:6.1 KD. Males: weight t-test t= 0.2, n.s.; glucose t=−0.6, n.s.; β-hydroxybutyrate t=−7.6, ⁎⁎⁎p b 0.001.
144 D.N. Ruskin et al. / Physiology & Behavior 168 (2017) 138–145treatments such as ketone esters are warranted in ASD patients and
models.
Of additional clinical importance, KDs do notworsen ASD-associated
behaviors and there is evidence they may restore homoeostasis [25].
Previously we and others published the lack of a KD effect in control
mouse and rat strains on behavior and electrophysiology in a variety
of paradigms. In normally social control strains, we found KD feeding
produced no signiﬁcant change in sociability or in STFP; in control
strains with normal grooming levels, KD similarly produced no change
[39]. We also found a lack of effect of KD feeding on working memory
in control mouse strains [48] and a lack of effect on baseline hippocam-
pal electrophysiology in vitro in control strains (but an impact on chem-
ically-induced epileptiform activity; [56]). We found normal in vivo
baseline hippocampalﬁeld potential activity (but a lessening of induced
seizures or tetanus-induced potentiation; [53,54,57]. Work from other
laboratories is largely in agreement (for instance [76,77]). Overall, KDs
and ketosis have negligible effects in animals that are normal and in sys-
tems that are unperturbed.
Given the lack of effective drug treatments against poor sociability
and communication, the limited effectiveness of drug treatments
against stereotypical behaviors, and the undesirable side effects of
these drugs [78], KDs and similar treatments are particularly attractive
for ASD as non-pharmacological approaches that aid with these core
symptoms. A metabolic approach is well established and represents a
mechanistically new type of treatment for ASD. In epilepsy, KDs are as
effectively anticonvulsant as the commonly-used anticonvulsant drugs
[16,79–82]; KDs may prove to surpass medications in effectiveness
against ASD core symptoms. Based on the present and prior research
[27,51], KD feeding treats both seizures and ASD-like symptoms in the
EL mouse model of comorbid epilepsy/ASD - therefore, KDs may merit
special consideration as a treatment for autistic patients with this
same comorbidity. In epilepsy, chronic KD treatment can produce sei-
zure control that extends well beyond cessation of the diet (e.g. [83–
85]) suggesting a persistent, possibly epigenetic, effect [32] – it remains
to be seen if KD amelioration of ASD symptoms can persist in a similar
manner. Finally, although ASD is more common in males, our positive
results in femalesmay provide additional hope for the 4 in 1000 females
(650,000 individuals in the USA) who have ASD [86].
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